GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Net Income From Continuing Operations

AngioLab (XKRX:251280) Net Income From Continuing Operations : ₩-2,320.7 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is AngioLab Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. AngioLab's net income from continuing operations for the six months ended in Dec. 2023 was ₩-2,320.7 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-2,320.7 Mil.

AngioLab Net Income From Continuing Operations Historical Data

The historical data trend for AngioLab's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioLab Net Income From Continuing Operations Chart

AngioLab Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
Get a 7-Day Free Trial -8,083.80 -850.37 -2,069.93 -2,011.16 -2,320.70

AngioLab Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial -8,083.80 -850.37 -2,069.93 -2,011.16 -2,320.70

AngioLab Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 was ₩-2,320.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioLab (XKRX:251280) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AngioLab Inc (XKRX:251280) » Definitions » Net Income From Continuing Operations
Comparable Companies
XKRX:072520 XKRX:446440 XKRX:215380 XKRX:322970 XKRX:283100 XKRX:950220 XKRX:343090 XKRX:179530 XKRX:388610 XKRX:208340 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
65 Techno 3ro, Suite 159, Hanshin S Mecca, Yuseong-gu, Doejeon, CHN
Website
http://www.angiolab.co.kr
AngioLab Inc is a biotechnology company. It develops products based on angiogenesis inhibitors. It discovers, develops, and markets anti-angiogenic candidates to inhibit the abnormal growth of new blood vessel.

AngioLab (XKRX:251280) Headlines

No Headlines